Myeloma Action Month to focus on bringing hope through action
Myeloma Action Month (MAM) is observed each March to call attention to multiple myeloma and the people affected by it, and this year’s…
News
FDA OKs less frequent Tecvayli dosing for treatment responders
The U.S. Food and Drug Administration (FDA) has cleared an every-other-week dosing regimen of Tecvayli (teclistamab) for relapsed or refractory (hard-to-treat) multiple myeloma…
Elrexfio now approved in Canada as recurring myeloma treatment
Health Canada has granted conditional approval to Pfizer’s Elrexfio (elranatamab-bcmm), expanding the list of countries where the medication can be used for adults with…
Blenrep delays disease progression by nearly 3X versus Darzalex
GlaxoSmithKline (GSK)’s Blenrep (belantamab mafodotin) significantly reduced by more than half the risk of disease progression or death in people with relapsed or refractory…
Regeneron seeking approval of linvoseltamab for RRMM in US, EU
The European Medicines Agency has agreed to review Regeneron Pharmaceuticals’ application seeking approval of its investigational therapy linvoseltamab for adults in Europe with relapsed…
Abecma wins CHMP’s thumbs up for use in earlier treatment lines
Bristol Myers Squibb has received a positive opinion from an arm of the European Medicines Agency (EMA) on the use of its CAR T-cell…
Treating hepatitis may improve patient outcomes in myeloma
A dysregulated immune response against viruses that cause hepatitis may lead to some cases of multiple myeloma (MM) — and in these cases, treating…
Obesity, smoking, and poor sleep raise risk of myeloma precursor
Obesity, a history of heavy smoking, and limited sleep are risk factors for developing monoclonal gammopathy of undetermined significance (MGUS), a precursor condition to…
STAR-LLD combo showing potential for multiple myeloma in clinical trial
STAR-LLD, a continuous infusion of low-dose lenalidomide into the blood, shows the potential to be a better treatment choice than Revlimid, an oral formulation…
AstraZeneca to add CAR T-cell therapy to pipeline with Gracell buy
AstraZeneca is set to buy Gracell Biotechnologies in a deal worth up to $1.2 billion that would add GC012F — an experimental dual-targeting…
Recent Posts
- Vulvar cancer possibly tied to bacteria not known in such cancers
- New atlas details immune cell changes as disease progresses
- FDA approves Imkeldi, imatinib as oral liquid, for certain leukemias
- Somatostatin may be safe option for certain tumors during pregnancy
- Vitamin D seen to prevent ovarian cancer’s onset in disease models